aIdentity to full-length predicted protein. The predicted BapR protein sequence from B. cenocepacia H111 was used to search against the Burkholderia Genome Database (www.burkholderia.com) with the TBL
As part of the ACTIV-2/A5401 randomized clinical trial (NCT04518410), participants with symptomatic SARS-CoV-2 infection were given cilgavimab and tixagevimab or placebo treatment. We performed target
Dataset which consist of demographic data of the samples, gel electrophoresis image of PCR products and the accession numbers of referenced sequences from the Genbank.
All the positive samples were resistant to amantadine, none of influenza A (H3N2) and 2009 influenza A (H1N1) were resistant to oseltamivir, but all the five seasonal influenza A (H1N1), collected in